July 1, 2024
The following revisions were incorporated into the July 1, 2024 update.
Revisions
For the section “Reconstructive procedures and potentially cosmetic procedures", the title for the subsection “Gender reassignment surgery" changed to “Gender Affirming interventions".
Additions
Gender Affirming interventions 11920 Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin, including micropigmentation 11921 Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin, including micropigmentation 11922 Tattooing, intradermal introduction of insoluble opaque pigments to correct color defects of skin, including micropigmentation 15877 Suction Assisted Lipectomy; Trunk Genetically and bio-engineered skin substitutes for wound care Q4311 Acesso, per square centimeter Q4312 Acesso ac, per square centimeter Q4314 Reeva ft, per square cenitmeter Q4317 Vitograft, per square centimeter Q4318 E-graft, per square centimeter Q4319 Sanograft, per square centimeter Q4320 Pellograft, per square centimeter Q4321 Renograft, per square centimeter Q4322 Caregraft, per square centimeter Q4325 Acapatch, per square centimeter Q4326 Woundplus, per square centimeter Q4327 Duoamnion, per square centimeter Q4328 Most, per square centimeter Q4329 Singlay, per square centimeter Q4330 Total, per square centimeter Q4331 Axolotl graft, per square centimeter Q4332 Axolotl dualgraft, per square centimeter Q4333 Ardeograft, per square centimeter Amyotrophic Lateral Sclerosis agents
NurOwn® - J3490, J3590, and C9399 Antineoplastic agents Loqtorzi™ - J3263 Anti PD-1/PD-L1 human monoclonal antibodies Cosentyx® IV – J3247 Tevimbra® - J3490 and C9399
Enzyme replacement agents Adzynma - J7171 Gene Replacement / Gene Editing Therapies Lyfgenia™ - J3394 Zynteglo® - J3393 Immunological agents Omvoh™ - J2267 Wezlana – Q5137, Q5138 Intravenous Immune Globulin/Subcutaneous Immune Globulin (IVIG/SCIG) Intravenous Immune Globulin (IVIG) Alyglo™ - J1599 Neutropenia Ryzneuta® - J9361 Tumor Infiltrating Lymphocyte (TIL) Therapy Amtagyi™ – J3490, J3590, and C9399
Deletions Genetically and bio-engineered skin substitutes for wound care Q4210 Axolotl graft or axolotl dualgraft, per square centimeter Q4277 Woundplus membrane or e-graft, per square centimeter Amyotrophic Lateral Sclerosis agents Debamestrocel (pending FDA approval) - J3490, J3590, and C9399 Anti PD-1/PD-L1 human monoclonal antibodies Tislelizumab (pending FDA approval) - J3490 and C9399 Toripalimab (pending FDA approval) - J3490 and C9399 Enzyme replacement agents Apadamtase Alfa (pending FDA approval) - J3490, J3590, and C9167 Gene Replacement / Gene Editing Therapies Lyfgenia™ - J3490, J3590, and C9399 Zynteglo® - J3590 and C9399 Immunological agents Omvoh™ - J3490, J3590, and C9168 Neutropenia Ryzneuta® - J3590 and C9399 Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel (pending FDA approval) – J3490, J3590, and C9399
|